LAUSR

1. Casini A, de Moerloose P, Neerman-Arbez M. Clinical features and management of congenital fibrinogen deficiencies. Semin Thromb Hemost. 2016;42:366-374. 2. Peyvandi F, Palla R. Fibrinogen concentrates. Clin Adv Hematol Oncol. 2009;7:788-790. 3. Mensah PK, Oppenheimer C, Watson C, Pavord S. Congenital afibrinogenaemia in pregnancy. Haemophilia. 2011;17:167-168. 4. Kobayashi T, Asahina T, Maehara K, Itoh M, Kanayama N, Terao T. Congenital afibrinogenemia with successful delivery. Gynecol Obstet Invest. 1996;42:66-69. 5. Trehan AK, Fergusson IL. Congenital afibrinogenaemia and successful pregnancy outcome. Case report. Br J Obstet Gynaecol. 1991;98:722-724. 6. Roque H, Stephenson C, Lee MJ, et al. Pregnancyrelated thrombosis in a woman with congenital afibrinogenemia: a report of two successful pregnancies. Am J Hematol. 2004;76:267-270. 7. Oda T, Itoh H, Kawai K, et al. Three successful deliveries involving a woman with congenital afibrinogenaemia–conventional fibrinogen concentrate infusion vs.’as required’fibrinogen concentrate infusion based on changes in fibrinogen clearance. Haemophilia. 2016;22:478-481. 8. Peyvandi F. Epidemiology and treatment of congenital fibrinogen deficiency. Thromb Res. 2012;130(Suppl 2):S7-S11. 9. Kreuz W, Meili E, Peter-Salonen K, et al. Pharmacokinetic properties of a pasteurised fibrinogen concentrate. Transfus Apher Sci. 2005;32:239-246. 10. Blondon M, Casini A, Hoppe KK, Boehlen F, Righini M, Smith NL. Risks of venous thromboembolism after cesarean sections: a metaanalysis. Chest. 2016;150:572-596. 11. de Bosch NB, Mosesson MW, Ruiz-Saez A, Echenagucia M, RodriguezLemoin A. Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I). Thromb Haemost. 2002;88:253-258.